Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases

T. Qaradakhi, LK. Gadanec, KR. McSweeney, A. Tacey, V. Apostolopoulos, I. Levinger, K. Rimarova, EE. Egom, L. Rodrigo, P. Kruzliak, P. Kubatka, A. Zulli

. 2020 ; 47 (5) : 751-758. [pub] 20200128

Jazyk angličtina Země Austrálie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026708

The renin angiotensin system (RAS) regulates fluid balance, blood pressure and maintains vascular tone. The potent vasoconstrictor angiotensin II (Ang II) produced by angiotensin-converting enzyme (ACE) comprises the classical RAS. The non-classical RAS involves the conversion of Ang II via ACE2 into the vasodilator Ang (1-7) to counterbalance the effects of Ang II. Furthermore, ACE2 converts AngA into another vasodilator named alamandine. The over activation of the classical RAS (increased vasoconstriction) and depletion of the non-classical RAS (decreased vasodilation) results in vascular dysfunction. Vascular dysfunction is the leading cause of atherosclerosis and cardiovascular disease (CVD). Additionally, local RAS is expressed in various tissues and regulates cellular functions. RAS dysregulation is involved in other several diseases such as inflammation, renal dysfunction and even cancer growth. An approach in restoring vascular dysfunction and other pathological diseases is to either increase the activity of ACE2 or reduce the effect of the classical RAS by counterbalancing Ang II effects. The antitrypanosomal agent, diminazene aceturate (DIZE), is one approach in activating ACE2. DIZE has been shown to exert beneficial effects in CVD experimental models of hypertension, myocardial infarction, type 1 diabetes and atherosclerosis. Thus, this review focuses on DIZE and its effect in several tissues such as blood vessels, cardiac, renal, immune and cancer cells.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026708
003      
CZ-PrNML
005      
20211026132703.0
007      
ta
008      
211013s2020 at f 000 0|eng||
009      
AR
024    7_
$a 10.1111/1440-1681.13251 $2 doi
035    __
$a (PubMed)31901211
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a at
100    1_
$a Qaradakhi, Tawar $u Institute for Health and Sport, Victoria University, Melbourne, Australia
245    14
$a The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases / $c T. Qaradakhi, LK. Gadanec, KR. McSweeney, A. Tacey, V. Apostolopoulos, I. Levinger, K. Rimarova, EE. Egom, L. Rodrigo, P. Kruzliak, P. Kubatka, A. Zulli
520    9_
$a The renin angiotensin system (RAS) regulates fluid balance, blood pressure and maintains vascular tone. The potent vasoconstrictor angiotensin II (Ang II) produced by angiotensin-converting enzyme (ACE) comprises the classical RAS. The non-classical RAS involves the conversion of Ang II via ACE2 into the vasodilator Ang (1-7) to counterbalance the effects of Ang II. Furthermore, ACE2 converts AngA into another vasodilator named alamandine. The over activation of the classical RAS (increased vasoconstriction) and depletion of the non-classical RAS (decreased vasodilation) results in vascular dysfunction. Vascular dysfunction is the leading cause of atherosclerosis and cardiovascular disease (CVD). Additionally, local RAS is expressed in various tissues and regulates cellular functions. RAS dysregulation is involved in other several diseases such as inflammation, renal dysfunction and even cancer growth. An approach in restoring vascular dysfunction and other pathological diseases is to either increase the activity of ACE2 or reduce the effect of the classical RAS by counterbalancing Ang II effects. The antitrypanosomal agent, diminazene aceturate (DIZE), is one approach in activating ACE2. DIZE has been shown to exert beneficial effects in CVD experimental models of hypertension, myocardial infarction, type 1 diabetes and atherosclerosis. Thus, this review focuses on DIZE and its effect in several tissues such as blood vessels, cardiac, renal, immune and cancer cells.
650    _2
$a angiotensin-konvertující enzym 2 $x metabolismus $7 D000085962
650    _2
$a zvířata $7 D000818
650    _2
$a kardiovaskulární nemoci $x farmakoterapie $x enzymologie $x patofyziologie $7 D002318
650    _2
$a diminazen $x škodlivé účinky $x analogy a deriváty $x terapeutické užití $7 D004133
650    _2
$a aktivace enzymů $7 D004789
650    _2
$a aktivátory enzymů $x škodlivé účinky $x terapeutické užití $7 D020536
650    _2
$a lidé $7 D006801
650    _2
$a nádory $x farmakoterapie $x enzymologie $x patofyziologie $7 D009369
650    _2
$a renin-angiotensin systém $x účinky léků $7 D012084
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Gadanec, Laura Kate $u Institute for Health and Sport, Victoria University, Melbourne, Australia
700    1_
$a McSweeney, Kristen Renee $u Institute for Health and Sport, Victoria University, Melbourne, Australia
700    1_
$a Tacey, Alexander $u Institute for Health and Sport, Victoria University, Melbourne, Australia $u Australian Institute for Musculoskeletal Science (AIMSS), University of Melbourne and Western Health, St Albans, Australia
700    1_
$a Apostolopoulos, Vasso $u Institute for Health and Sport, Victoria University, Melbourne, Australia
700    1_
$a Levinger, Itamar $u Institute for Health and Sport, Victoria University, Melbourne, Australia $u Australian Institute for Musculoskeletal Science (AIMSS), University of Melbourne and Western Health, St Albans, Australia
700    1_
$a Rimarova, Kvetoslava $u Department of Public Health and Hygiene, Faculty of Medicine, Pavol Jozef Safarik University, Kosice, Slovakia
700    1_
$a Egom, Emmanuel E $u Egom Clinical & Translational Research Services Ltd, Dartmouth, NS, Canada $u Jewish General Hospital and Lady Davis Research Institute, Montreal, QC, Canada
700    1_
$a Rodrigo, Luis $u Faculty of Medicine, University of Oviedo and Central University Hospital of Asturias (HUCA), Oviedo, Spain
700    1_
$a Kruzliak, Peter $u Department of Internal Medicine, Borthers of Mercy Hospital, Brno, Czech Republic $u 2nd Department of Surgery, Faculty of Medicine, Masaryk University and St. Anne's University Hospital, Brno, Czech Republic
700    1_
$a Kubatka, Peter $u Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia $u Division of Oncology, Biomedical Center Martin, Jessenius Faculty of Medicine, Comenius University in Bratislava, Martin, Slovakia
700    1_
$a Zulli, Anthony $u Institute for Health and Sport, Victoria University, Melbourne, Australia
773    0_
$w MED00007158 $t Clinical and experimental pharmacology & physiology $x 1440-1681 $g Roč. 47, č. 5 (2020), s. 751-758
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31901211 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132709 $b ABA008
999    __
$a ok $b bmc $g 1715445 $s 1147215
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 47 $c 5 $d 751-758 $e 20200128 $i 1440-1681 $m Clinical and experimental pharmacology & physiology $n Clin Exp Pharmacol Physiol $x MED00007158
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace